CS
RPTX

Credit Suisse’s Repare Therapeutics RPTX Stock Holding History

Credit Suisse’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-26,970
Closed -$326K – 3134
2023
Q3 		$326K Sell
26,970
-951
-3% -$9.82K ﹤0.01% 2903
2023
Q2 		$295K Buy
27,921
+5,698
+26% +$58.7K ﹤0.01% 3008
2023
Q1 		$219K Buy
22,223
+930
+4% +$10.7K ﹤0.01% 3088
2022
Q4 		$313K Buy
21,293
+6,873
+48% +$103K ﹤0.01% 3013
2022
Q3 		$176K Buy
14,420
+8
+0.1% +$103 ﹤0.01% 3293
2022
Q2 		$202K Buy
14,412
+2,203
+18% +$25.9K ﹤0.01% 3323
2022
Q1 		$175K Buy
+12,209
New +$181K ﹤0.01% 3400
2021
Q3 		– Sell
-6,454
Closed -$201K – 4519
2021
Q2 		$201K Sell
6,454
-2,062
-24% -$67.5K ﹤0.01% 4277
2021
Q1 		$261K Buy
+8,516
New +$289K ﹤0.01% 4038

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Credit Suisse's RPTX Position: Q4 2023 in Review

Credit Suisse sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 26,970 shares — an estimated $326K sold.

Credit Suisse first reported a position in RPTX in Q1 2021 and held it in 9 quarters. The position peaked at $326K in Q3 2023. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • Credit Suisse reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 26,970 Repare Therapeutics shares in Q4 2023, an estimated $326K.
  • Credit Suisse first reported a position in Repare Therapeutics in Q1 2021 and held it in 9 quarters.
  • Credit Suisse's Repare Therapeutics position peaked at $326K in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.